Bellicum制药

BLCM NASDAQ
0.9659
+0.0182
+1.92%
盘后: 1.050 +0.084 +8.71% 18:16 08/22 EDT
开盘
1.040
昨收
0.9477
最高
1.050
最低
0.9354
成交量
97.55万
成交均量(3M)
72.43万
52周最高
7.26
52周最低
0.7800
换手率
2.11%
市值
4,467.69万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Bellicum制药 BLCM股票价格,Bellicum制药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.
展开 >

最近浏览

名称
价格
涨跌幅